VitaeBiomedical Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
VITAE Biomedical offers a Urine‑based Lung Cancer ELISA Reagent Kit, which uses dual highly specific antibodies in a sandwich assay to detect lung cancer–associated proteins in urine. The test shows high sensitivity and specificity, is CE‑certified in the
The content above was translated by Ai
Founded Year
2017
Unified Business No.
55623255
Status
Active
Number of Employees
0
Total Paid-in
Capital
115,102,000 (NT$)
Location of Company
Taiwan
, Taipei City
Overseas Development
Japan
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
VITAE Biomedical Co., Ltd., founded in 2019, is a molecular diagnostics biotech company focused on developing fast, accurate, and cost-effective automated cancer screening technologies. Their R&D team, primarily from Academia Sinica, aims to bring real-world clinical diagnostic tools to early disease detection and health management.
The content above was translated by Ai
